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The BCL6 gene, mapped at the chromosomal band 3q27,
encodes a POZ/Zinc finger transcription repressor
protein. It is frequently activated in Non-Hodgkin’s
lymphomas (NHL) by translocations with breakpoints
clustering in the 5' major breakpoint region (MBR) as
well as by mutations in the same region. The
translocations lead to BCL6 activation by substitution
of promoters of rearranging genes derived from the
reciprocal chromosomal partners such as IG. We report
the molecular genetic analysis of a novel t(2;3)(q21;q27)
translocation subset in NHL comprising three cases
without apparent BCL6 involvement in the translocation.
Southern blot analysis of tumor DNAs utilizing BCL6
MBR probes revealed no rearrangement in two cases.
Two rearranged bands in the third case resulted from a
deletion in one allele and a mutation in the other allele.
Southern blot analysis of DNA from one of the two
tumors without BCL6 rearrangement, using a probe
derived from the recently identified alternative break-
point region (ABR), showed a rearrangement. The ABR
is located 200 – 270 kb telomeric to MBR. Mutations
were identified in the previously reported hypermutable
region of BCL6 in all three tumors. In one, the mutant
allele alone was found to be expressed by RT–PCR
analysis of RNA. These results demonstrate the presence
of 3q27 translocation breakpoints at a distance from
BCL6 suggesting distant breaks that deregulate the gene
or involvement of other genes that may be subject to
rearrangement.
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Introduction
Chromosomal translocations aecting band 3q27 have
been noted to occur frequently in diuse large cell
lymphoma (DLCL) and other subsets of non-
Hodgkin’s lymphoma (NHL) (Ot et al., 1989;
Bastard et al., 1992). By molecular genetic analysis of
t(3;14) (q27;q32) translocations, the BCL6 gene was
isolated and mapped to 3q27 adjacent to the
chromosomal breakpoint (Baron et al., 1993; Ker-
ckaert et al., 1993; Ye et al., 1993a; Miki et al., 1994).
The BCL6 gene encodes a POZ/Zinc finger transcrip-
tion factor which functions as a sequence specific
transcription repressor (Deweindt et al., 1995; Chang et
al., 1996; Seyfert 1996; Baron et al., 1997). The primary
function of BCL6 appears to be regulation of germinal
center (GC) development and T-cell directed immune
response (Dent et al., 1997; Ye et al., 1997). Activating
BCL6 rearrangements have been shown to result from
chromosomal translocations with IG or other loci that
alter BCL6 expression by promoter substitution, or
from point mutations in the 5' regulatory region
(Migliazza et al., 1995; Ye et al., 1995; Chen et al.,
1998). The rearrangements cluster in a major break-
point region (MBR) mapped to the first non-coding
exon and 5' of the first intron (Ye et al., 1993b). More
recently, an alternative breakpoint region (ABR) to the
MBR was identified in B-cell NHL at 3q27 and shown
to be located 200 – 270 kb in the telomeric direction of
BCL6 (Butler et al., 1997). BCL6 mutations, which
have been noted in 73% of DLCLs and 47% of
follicular lymphomas (FL), cluster in a *730 bp
noncoding region which spans the first exon-intron
boundary (Migliazza et al., 1995). Recent studies also
identified recurrent deletions in the MBR region,
independent of chromosomal rearrangements (Naka-
mura et al., 1996; Bernardin et al., 1997).
We and others have shown that 3q27 promiscuous
translocations involve multiple partner chromosomal
sites such as 1q21, 2q21, 4q21, 5q13, 11q13, 12q24 and
15q21 (Ye et al 1993a; Wlodarska et al., 1995).
Recently, three genes, TTF, BOB1 and H4, have been
identified by cloning the BCL6 breakpoints in tumors
with t(3;4)(q27;p11), t(3;11)(q27;q23) and t(3;6)
(q27;p21) translocations, respectively (Dallery et al.,
1995; Galiegue-Zouitina et al., 1995; Akasaka et al.,
1997). We report here the results of molecular genetic
analysis of a novel t(2;3)(q21;q27) subset in NHL, in
which the BCL6 gene exhibits deletions and point
mutations in the 5' regulatory region; however, the
translocation breakpoint is at a distance upstream of
the locus.
Results
Southern blot analysis of rearrangements
In an attempt to detect BCL6 rearrangements in the
three tumors, Southern blot analysis was performed on
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available genomic DNA digested with the restriction
enzymes BamHI, XbaI, and HindIII using genomic
probes spanning the MBR and ABR. No rearrangement
was detected with the MBR probes in tumors 1187 and
1562. In the case of tumor 1254, one rearranged BamHI
fragment and two rearranged XbaI fragments were
detected upon hybridization with the probe pGS4.0
(Figures 1 and 2a). A genomic library constructed from
this tumor was screened with the same probe, which
yielded six BCL6 positive clones. Mapping analysis of
these clones identified two rearrangement fragments. In
one, the rearrangement resulted from a 2.3 kb deletion
within a 3.4 kb EcoRI fragment spanning the first exon
and the 5' region of the first intron, while the other
resulted from a point mutation that generated a new
XbaI site in the first exon (Figure 2b). Both alterations
were located in the previously identified hypermutable
region (Migliazza et al., 1995). Further subcloning and
sequencing of the rearranged fragments identified
additional subtle mutations (Figures 2b and 3).
In tumor 1562, the ABR probe (XN 1.3) detected
rearrangement with two restriction enzymes (Figure 4).
Thus, the t(2;3)(q21;q27) translocation in this case is
most likely associated with a chromosomal break
occurring within the ABR at 3q27 200 – 270 kb
telomeric to BCL6. No rearrangement was noted in
tumor 1187, while DNA for similar analysis was
unavailable for tumor 1254.
Figure 1 Southern blot analysis of DNA from tumor 1254
showing DNA rearrangements in BCL6 with the probe pGS4.0.
Arrows point to rearranged bands. PL = placental DNA (normal
control)
Figure 2 (a) Restriction map of BCL6 showing the probes used in Southern blotting analysis (pGS4.0, pGRB 5.1 and pGFB1.8),
B, BamHI; X XbaI. Open boxes represent non-coding exon regions and filled boxes represent coding exon regions. (b) Schematic
representation of the BCL6 mutations found in tumor 1254 in the region surrounding the first exon. In allele A, a point mutation of
G to A generated a new XbaI restriction site (TCTAGA) in exon 1. The hatched box covers the region with all the mutations
detected, the frequency of each type of mutation is also shown. In allele B, the dotted line identifies the deletion. An inversion and
another deletion also were noted 3' of this deletion. Pa and Pb denote BCL6 promoters. R, S, and X indicate the restriction enzymes
EcoRI, SacI, and XbaI, respectively
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FISH analysis
FISH analysis was also performed on interphase nuclei
from tumors 1254 and 1562 using the PAC-133-MI9
and P1-371-08 and YAC 19G10 (Figure 4). No split
signal was detected in 100 interphase nuclei from each
tumor following hybridization with the PAC and P1
probes, while the YAC hybridization results were
uninformative due to high repeat sequence content.
Lymphoma cells suitable for FISH analysis were not
available from tumor 1187.
PCR–SSCP analysis of mutations
Mutation analysis was performed on tumors 1187 and
1562 by PCR–SSCP of BCL6 sequences flanking the
hypermutable region using previously described pri-
mers (Mgliazza et al., 1995). SSCP variants were
observed in the PCR fragments El.11 and El.14,
representing the first exon and exon-intron boundary
in both tumors (Figure 5).
Identification of the expressed allele in tumor 1254 by
RT –PCR
The biallelic nature of the mutations observed in tumor
1254 prompted us to analyse the expression of the two
alleles. For this, RT –PCR was performed using RNA
isolated from a snap-frozen biopsy of the tumor. Since
the deletions occurred almost at the beginning of the
BCL6 transcript, the 5' anchor primer was adapted for
amplification of the CDNA. The final PCR product
amplified by the 5' anchor primer and primer 567 at
exon 4 yielded * 400 bp fragment on the agarose gel,
corresponding to the BCL6 germline fragment (Figure
6). No variant transcript corresponding to allele B with
the deletion was detected. The 400 bp PCR fragment
was subloned into pGEM-T vector (Promega) and
sequenced. The point mutation in allele A that
generated a new XbaI site (Figure 2b) was found in all
of the 10 selected cDNA clones. These results suggest
that the only expressed BCL6 allele in this tumor was
the mutated allele.
Discussion
The majority of B cell NHLs exhibit recurring
chromosomal translocations involving the IG genes
and several proto-oncogenes. At the molecular genetic
level, such translocation analysed in the greatest detail
comprise those associated with Burkitt’s lymphoma
(BL) and FL, wherein the expression of MYC and
BCL2 genes, respectively, is deregulated as a result of
translocations which juxtapose these genes with one of
the IG loci (Dalla-Favera et al., 1982; Taub et al., 1982;
Bakhshi et al., 1985). In contrast, translocations
aecting BCL6 are promiscuous and involve multiple
gene partners, in addition to the IG genes. More than
17 dierent chromosomal sites have been identified
which participate in translocations with 3q27 (Bastard
et al., 1992; Ye et al., 1993a; Wlodarska et al., 1995).
We have recently shown that heterologous promoters
fused to BCL6 in these translocations lead to its
persistent expression beyond its developmentally
regulated point of downregulation during B-cell
development, leading to lymphomagenesis (Chen et
al., 1998).
Here we report the molecular genetic analysis of the
t(2;3)(q21;q27) translocation subset comprising one
case each of FSCL, FMxL, and DLCL. To date, this
translocation has been reported in four cases of NHL
(Kornblau et al., 1991; Konishi et al., 1990; Bloomfield
et al., 1983; Benitze et al., 1992), thus identifying a new
subset of recurring translocation in NHL. Notably, the
t(2;3)(q21;q27) translocation was the only chromoso-
mal abnormality in case 1254.
No BCL6 rearrangements associated with the
chromosomal translocation was detected within the
MBR or 100 kb 5' of the BCL6 locus in any of the
three tumors by Southern blot and/or FISH analysis,
suggesting the presence of variant breakpoint(s) at a
distance from BCL6. Consistent with this finding, in a
recent study by us, 50% of NHL with 3q27
chromosomal rearrangements failed to exhibit BCL6-
MBR rearrangements (Chaganti et al., 1998). Wlo-
darska et al. (1995) also were unable to detect a BCL6-
MBR rearrangement in a case of NHL with a
t(1;3)(q21;q27) translocation by FISH analysis. In one
tumor (1562) we localized the 3q27 breakpoint to the
recently identified ABR, 200 – 270 kb telomeric to
BCL6. This and other possible distant breakpoints
may harbor long range regulatory element(s) capable
of deregulating BCL6 expression. Studies of BL
translocations have shown that the t(8;14)(q24;q32)
translocation breakpoints can be as far as 300 kb
Figure 3 BCL6 mutations detected by sequencing in tumor 1254.
A mutation in the exon 1 region that generated a new XbaI
restriction site is shown. The sequence shown here represents the
antisense strand. Arrow points to the mutation, the solid line on
the side indicates the XbaI site. DNA sequence derived from the
normal counterpart of the patient 1254 was used as a negative
control
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upstream or downstream of MYC, in addition to the
apparent cluster region surrounding the first exon (Joos
et al., 1992; Axelson et al., 1994). Alternatively, other
oncogene(s) upstream of BCL6 may be deregulated by
the translocation(s) or exert long-range influence on
BCL6 expression.
As previously noted in the other DLCLs, the BCL6
gene in all these cases studied exhibited mutations and/
or deletion in the region spanning the exon1-intron1
boundary. By RT–PCR analysis of BCL6 expression
in tumor 1254, we have shown that the allele with the
deletion probably is silent, possibly due to loss of the
preferred promoter (pb) 3' of the first exon. The fact
that the mutated allele appeared to be the only
expressed allele in this translocation is consistent with
the role of mutation in BCL6 activation. The mutation
analysis of the three tumors with the t(2;3)(q21;q27)
translocation reported here is also consistent with our
previous observation that BCL6 mutation is indepen-
dent of rearrangement by translocation.
Figure 4 Mapping the 3q27-ABR breakpoint in tumor 1562. (a) Schematic representation of a 400 kb contig of P1, PAC, and
YAC clones from the genomic region of 3q27. The positions of BCL6 and associated MBR are indicated. The ABR is located
approximately 200 – 270 kb 5' (telomeric) to the BCL6 gene as determined by a combination of PFGE and hybridization analysis
(Butler et al., 1997). The ends of P1, PAC, and YAC clones serve as markers of overlap between adjacent clones, and are named
according to their clone of origin, followed by their primer derivation (T7 or SP6 for P1/PAC) or orientation (left (L) or right (R)
for YAC). The point of overlap between clones is indicated by the vertical dashed lines on the map. Probe XN 1.3 was isolated from
a genomic phage l-15-1952 contained within the ABR. (b). Southern blot showing rearrangement in tumor 1562 DNA using probe
XN 1.2 from ABR. Arrowheads indicate the rearranged restriction fragments
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Materials and methods
Tumor ascertainment and cytogenetics
Tumors 1187, 1254 and 1562 were part of a previously
described ascertainment of NHL at the Memorial Sloan-
Kettering Cancer Center (MSKCC) (Ot et al., 1994). The
tumors were diagnosed based on histopathologic, immu-
nophenotypic, and immunogenotypic analysis as described
previously (Ot et al., 1994). Cytogenetic analysis of
disaggregated lymph node cells was performed following
short-term culture, chromosome preparation, and G-
banding, according to conventional methods. Each tumor
specimen revealed a t(2;3)(q21;q27) translocation. Case
1187 was a 54-year-old male with follicular small-cleaved
cell lymphoma (FSCL) with the chromosomal comple-
ment: 48,XY, t(2;3)(q21;q27),i(6)(p10),+12,der(12)t(1;12)
(q21;q22),t(14;18) (q32;q21),+21[10]. Case 1254 was a 74-
year-old female with a DLCL with the chromosomal
complement: 46,XX, t(2;3)(q21;q27) [2] /46, XX [23]. Case
1562 was a 72-year-old female with a follicular mixed
lymphoma (FMxL) with the chromosomal complement:43-
46, XX, t(2;3) (q21;q27), t(3;8) (q27;q13), del(6) (q21q27),
710,716,+mar1,+mar2, +mar3[cp15].
Fluorescence in situ hybridization (FISH) analysis of BCL6
genomic locus
The PAC clone 133M19 which covers the 100 kb upstream
of BCL6 was labeled with biotin-14-dUTP by nick
translation and hybridized to interphase nuclei from
tumor cells. Hybridization signals were visualized with
FITC-conjugated avidin (Oncor) following staining with
propidium iodide.
Analysis of BCL6 rearrangements by Southern blotting and
cloning of the rearranged bands
Genomic DNA from the the tumor biopsies and placental
control DNAs were digested with the restriction enzymes
BamHI and XbaI, electrophoresed on a 0. 8% agarose gel,
and transferred to a nylon membrane (Oncor). The blot
was hybridized sequentially with the BCL6-MBR probes
pGS4.0 (a 4 kb SacI fragment), pGRB5.1 (a 5.1 kb EcoRI/
BamHI fragment), and pGFB1.8 (a 1.8 kb BamHI
fragment) (Figure 2a). In the case of tumor 1562, DNA
digested with HindIII and BamHI was also hybridized with
the ABR probe XN 1.3. A genomic library of tumor 1254
was prepared by Sau3A partial digestion of DNA followed
by ligation into lambda GEM-11 (Promega). The library
was screened with the pGS4.0 probe. Positive clones were
selected and mapped. Rearranged fragments were sub-
cloned into pGEM-7Zf(7) (Promega) and sequenced.
Mutation analysis and expression of BCL6 alleles by RT –PCR
Genomic DNAs isolated from tumors 1187, 1562, Lyl, a
DLCL cell line (Tweeddale et al., 1987) (positive control)
and placenta (negative control) were amplified by PCR
with primers spanning the first exon and the 5' end of the
first intron as previously described (Migliazza et al., 1995).
SSCP analysis was performed according to described
methods (Xu et al., 1994). For 5' anchor RT – PCR
analysis, total RNA was isolated from a snap-frozen
sample of tumor 1254 using the RNAgents reagent
(Promega). 5'RACE analysis of the BCL6 transcripts was
performed using the 5'RACE kit (GIBCO/BRL) following
manufacturer’s recommendations. The primers used for
cDNA amplification were as previously described (Ye et
al., 1997), except that the reverse primer 567 (AGGGTT-
GATCTCAGGATC) at exon 4 was also used for the final
amplification. The final PCR product was subcloned into
PGEM-T (Promega) and sequenced.
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Figure 5 Mutations in the first exon/intron boundary of BCL6
detected by PCR/SSCP analysis. Representative results from PCR
products E1.11 and E1.14 at the exon-intron 1 boundary from
tumors 1187 and 1562. Arrows point to bands representing
conformation changes. DNA from placenta (N) and Ly1, a
DLCL cell line previously documented to have a mutation
(Migliazza et al., 1995) were used as negative and positive
controls, respectively
Figure 6 BCL6 expression detected by 5' anchor RT–PCR. The
first strand cDNA derived from patient 1254 was subjected to
PCR amplification with 5' anchor forward primer (GIBCO/BRL)
and reverse primer 567. The fragment sizes of the marker fX174
RF DNA/HaeIII are indicated
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